IUCRO-0498; Role of Osteocytes in Myeloma Bone Disease

Investigating Bone Destruction Markers in Myeloma: A Cancer Affecting Plasma Cells

Recruiting
18 years - 95 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to learn if substances that may cause bone destruction are increased in blood or bone marrow.

Detailed description of study

The investigators hope to determine serum FGF23 and heparanase, Dkk1 and plasma klotho levels in patients with newly diagnosed and relapsed myeloma compared to healthy controls with this exploratory study.

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Healthy,Multiple Myeloma
  • Age: 18 years - 95 years
  • Gender: All

Inclusion Criteria
English-speaking
Have no known liver or kidney disorders
Have no prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin
Exclusion Criteria
Pregnant
Allergic to xylocaine
Acute illness in the past seven days
History of bleeding disorders
Prisoners

Updated on 19 Feb 2024. Study ID: 1407589587

This study investigates if certain substances that might cause bone destruction are found in higher levels in the blood or bone marrow of people with myeloma. Myeloma is a type of cancer that affects plasma cells in the bone marrow. The study will compare these levels in patients with newly diagnosed and relapsed myeloma to healthy individuals.

Participants in the study will have their blood and bone marrow tested for specific substances. These include serum FGF23, heparanase, Dkk1, and plasma klotho levels. These tests will help researchers understand the differences between myeloma patients and healthy controls.

  • Who can participate: Participants must speak English, have no liver or kidney disorders, and no history of cancer in the past 5 years, except certain skin cancers. They should not be pregnant, allergic to xylocaine, have had a recent acute illness, bleeding disorders, or be prisoners.
  • Study details: Participants will undergo blood and bone marrow tests to measure levels of certain substances. These tests are part of the exploratory study to understand differences in myeloma patients.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here